Sökning: onr:"swepub:oai:DiVA.org:uu-445796" > Current challenges ...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 06635naa a2200841 4500 | |
001 | oai:DiVA.org:uu-445796 | |
003 | SwePub | |
008 | 210617s2021 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4457962 URI |
024 | 7 | a https://doi.org/10.1016/j.addr.2021.02.0012 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a for2 swepub-publicationtype |
100 | 1 | a Vinarov, Zahariu Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Leuven, Belgium; Sofia Univ, Dept Chem & Pharmaceut Engn, Sofia, Bulgaria4 aut |
245 | 1 0 | a Current challenges and future perspectives in oral absorption research :b An opinion of the UNGAP network |
264 | 1 | b Elsevier,c 2021 |
338 | a electronic2 rdacarrier | |
520 | a Although oral drug delivery is the preferred administration route and has been used for centuries, modern drug discovery and development pipelines challenge conventional formulation approaches and highlight the insufficient mechanistic understanding of processes critical to oral drug absorption. This review presents the opinion of UNGAP scientists on four key themes across the oral absorption landscape: (1) specific patient populations, (2) regional differences in the gastrointestinal tract, (3) advanced formulations and (4) food-drug interactions. The differences of oral absorption in pediatric and geriatric populations, the specific issues in colonic absorption, the formulation approaches for poorly water-soluble (small molecules) and poorly permeable (peptides, RNA etc.) drugs, as well as the vast realm of food effects, are some of the topics discussed in detail. The identified controversies and gaps in the current understanding of gastrointestinal absorption-related processes are used to create a roadmap for the future of oral drug absorption research. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Farmaceutiska vetenskaper0 (SwePub)301012 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Pharmaceutical Sciences0 (SwePub)301012 hsv//eng |
653 | a Specific patient populations | |
653 | a Regional differences | |
653 | a Advanced formulations | |
653 | a Amorphous solid dispersions | |
653 | a Lipid-based formulations | |
653 | a Food-drug interactions | |
653 | a Microbiome | |
653 | a In vitro tools | |
653 | a PBPK modeling | |
700 | 1 | a Abrahamsson, Bertilu AstraZeneca, Operat, Pharmaceut Technol & Dev, Oral Prod Dev, Gothenburg, Sweden4 aut |
700 | 1 | a Artursson, Peru Uppsala universitet,Institutionen för farmaci4 aut0 (Swepub:uu)perartur |
700 | 1 | a Batchelor, Hannahu Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, Glasgow, Lanark, Scotland4 aut |
700 | 1 | a Berben, Philippeu UCB Pharma SA, Pharmaceut Dev, Braine Lalleud, Belgium4 aut |
700 | 1 | a Bernkop-Schnürch, Andreasu Univ Innsbruck, Inst Pharm, Dept Pharmaceut Technol, Innsbruck, Austria4 aut |
700 | 1 | a Butler, Jamesu GlaxoSmithKline Res & Dev Ltd, Ware, Herts, England4 aut |
700 | 1 | a Ceulemans, Jensu Janssen Pharmaceut NV, Beerse, Belgium4 aut |
700 | 1 | a Davies, Nigelu AstraZeneca, R&D, Pharmaceut Sci, Adv Drug Delivery, Gothenburg, Sweden4 aut |
700 | 1 | a Dupont, Didieru STLO, Inst Agro, INRAE, Rennes, France4 aut |
700 | 1 | a Flaten, Gøril Eideu UiT Arctic Univ Norway, Dept Pharm, Tromsø, Norway4 aut |
700 | 1 | a Fotaki, Nikolettau Univ Bath, Dept Pharm & Pharmacol, Bath, Avon, England4 aut |
700 | 1 | a Griffin, Brendan T.u Univ Coll Cork, Sch Pharm, Cork, Ireland4 aut |
700 | 1 | a Jannin, Vincentu Lonza Pharma & Biotech, Colmar, France4 aut |
700 | 1 | a Keemink, Jannekeu Janssen Pharmaceut NV, Beerse, Belgium4 aut |
700 | 1 | a Kesisoglou, Filipposu Merck & Co Inc, Pharmaceut Sci, Rahway, NJ 07065 USA4 aut |
700 | 1 | a Koziolek, Mirkou Abbvie Deutschland GmbH & Co KG, Ludwigshafen, Germany4 aut |
700 | 1 | a Kuentz, Martinu Univ Appl Sci & Arts Northwestern Switzerland, Inst Pharma Technol, Basel, Switzerland4 aut |
700 | 1 | a Mackie, Alanu Univ Leeds, Sch Food Sci & Nutr, Leeds, W Yorkshire, England4 aut |
700 | 1 | a Meléndez-Martínez, Antonio J.u Univ Seville, Food Colour & Qual Lab, Area Nutr & Food Sci, Seville, Spain4 aut |
700 | 1 | a McAllister, Marku Pfizer PGRD, Drug Prod Design, Sandwich, Kent, England4 aut |
700 | 1 | a Müllertz, Anetteu Univ Copenhagen, Dept Pharm, Copenhagen, Denmark4 aut |
700 | 1 | a O'Driscoll, Caitriona M.u Univ Coll Cork, Sch Pharm, Cork, Ireland4 aut |
700 | 1 | a Parrott, Neilu F Hoffmann La Roche Ltd, Basel, Switzerland4 aut |
700 | 1 | a Paszkowska, Jadwigau Physiolut Polska Sp Zoo, Wroclaw, Poland4 aut |
700 | 1 | a Pavek, Petru Charles Univ Prague, Fac Pharm, Hradec Kralove, Czech Republic4 aut |
700 | 1 | a Porter, Christopher J. H.u Monash Univ, Monash Inst Pharmaceut Sci, Parkville, Vic, Australia4 aut |
700 | 1 | a Reppas, Christosu Natl & Kapodistrian Univ Athens, Dept Pharm, Athens, Greece4 aut |
700 | 1 | a Stillhart, Cordulau F Hoffmann La Roche Ltd, Basel, Switzerland4 aut |
700 | 1 | a Sugano, Kiyohikou Ritsumeikan Univ, Coll Pharmaceut Sci, Kusatsu, Shiga, Japan4 aut |
700 | 1 | a Toader, Elenau Univ Med & Pharm Iasi, Fac Med, Iasi, Romania4 aut |
700 | 1 | a Valentová, Katerinau Czech Acad Sci, Inst Microbiol, Prague, Czech Republic4 aut |
700 | 1 | a Vertzoni, Mariau Natl & Kapodistrian Univ Athens, Dept Pharm, Athens, Greece4 aut |
700 | 1 | a De Wildt, Saskia N.u Radboud Univ Nijmegen Med Ctr, Dept Pharmacol & Toxicol, Nijmegen, Netherlands4 aut |
700 | 1 | a Wilson, Clive G.u Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, Glasgow, Lanark, Scotland4 aut |
700 | 1 | a Augustijns, Patricku Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Leuven, Belgium4 aut |
710 | 2 | a Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Leuven, Belgium; Sofia Univ, Dept Chem & Pharmaceut Engn, Sofia, Bulgariab AstraZeneca, Operat, Pharmaceut Technol & Dev, Oral Prod Dev, Gothenburg, Sweden4 org |
773 | 0 | t Advanced Drug Delivery Reviewsd : Elsevierg 171, s. 289-331q 171<289-331x 0169-409Xx 1872-8294 |
856 | 4 | u https://doi.org/10.1016/j.addr.2021.02.001y Fulltext |
856 | 4 | u https://uu.diva-portal.org/smash/get/diva2:1568382/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
856 | 4 | u https://doi.org/10.1016/j.addr.2021.02.001 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-445796 |
856 | 4 8 | u https://doi.org/10.1016/j.addr.2021.02.001 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy